Close menu




NOVAVAX INC. DL-_01

Photo credits: pixabay.com

Commented by Juliane Zielonka on June 9th, 2022 | 12:25 CEST

wallstreet:online, Alibaba, Novavax - Digital pioneers and old hands

  • Investments
  • neobroker
  • Biotechnology

The number of young investors in Germany is rising steadily. To date, it stands at 49,000 people who are actively involved in their retirement planning. Both private and institutional investors are discovering the field of neobrokers as an investment. wallstreet:online AG is a candidate from the field with its own community. Alibaba founder Jack Ma has recognized that money has to keep moving in order to flow and is launching the first digital bank in Singapore. Things are somewhat more leisurely in the pharmaceutical sector: with Novavax, Americans now have four vaccines to choose from.

Read

Commented by André Will-Laudien on May 18th, 2022 | 12:48 CEST

Biotech stocks: BioNTech, XPhyto Therapeutics, Novavax, Valneva - Crashing, the choice remains difficult!

  • Biotechnology
  • Covid19

For pure play vaccine companies, the environment is getting tougher. On the one hand, the winter is over, and on the other, Corona has lost its horrors, especially as the Omicron variant presented like a cold for most infected people. 77.6% of the German population have received at least one vaccination dose so far. 63.1 million people have thus already received basic immunization, and 49.5 million people went for another shot. Only 4.6 million people, or 5.5%, have already received a second booster vaccination. 18.6 million people have not been vaccinated, or 22.4% of the population. With currently only 4,000 vaccinations per day, the many millions of vaccine doses ordered are likely to remain on the shelf. For vaccine manufacturers, future orders will plummet. Which Company has a plan B in place?

Read

Commented by Carsten Mainitz on February 24th, 2022 | 11:30 CET

SYNLAB, XPhyto, Novavax - How long will the Corona boom last?

  • Biotechnology

Corona has been turning the world upside down for two years. Although the stock markets have largely recovered from their crash in February and March 2020 and are clearly up again, some stocks are still doing much better, thanks to Corona. For example, shares of companies involved in developing and producing Corona vaccines, medicines, or testing methods have significantly outperformed the indices. But how sustainable is this boom?

Read

Commented by Carsten Mainitz on February 4th, 2022 | 12:22 CET

Novavax, Cardiol, MorphoSys - Here's the second wave of Corona vaccine plays!

  • Cannabis

The number of new Corona infections reported to the Robert Koch Institute (RKI) within one day has reached an all-time high. 236,120 additional cases were recorded, bringing the number of people in Germany who were confirmed to be infected with Sars-CoV-2 to 10.4 million. However, the number of unreported cases is significantly higher. Vaccine manufacturers from the early days have been able to clear the table in recent months, and now new companies such as Novavax and Valneva are entering the scene. But not all innovative approaches to fighting Corona are on the radar of investors. These are perfect conditions for a second share price wave.

Read

Commented by André Will-Laudien on February 3rd, 2022 | 13:55 CET

Novavax, XPhyto Therapeutics, BioNTech, Valneva - The vaccine blockbusters are on the move again!

  • Biotechnology

It is on again with the vaccine producers. Experts consider the pandemic to be over by the summer of 2022, but vaccination rates are still low, and infection figures are rushing from record to record. Meanwhile, mandatory vaccination by law is also a daily topic of discussion, dividing society into at least two camps. According to the thinking of those currently taking action, the right to freedom of bodily integrity probably ceases when third parties could suffer a disadvantage as a result of one's own decision. It's so easy to knit laws under the postulate of "protection & general welfare," and the individual right to liberty under the Basic Law is thus unceremoniously nullified. After all, members of parliament are supposed to be able to vote without factional coercion. We evaluate the chances of the well-known biotech protagonists!

Read

Commented by Armin Schulz on January 26th, 2022 | 11:17 CET

Novavax, CoinSmart, Netflix - A buy after significant setbacks?

  • Investments

The last few weeks have been tough for vaccine makers, cryptocurrencies and tech companies. In the case of vaccine manufacturers, concerns about a possible endemic disease caused by OmiCron was the reason for falling prices. In addition, there were the rumors about Pfizergate. Cryptocurrencies have been consolidating since early November. Allegedly, the US government is planning a crypto law, but contents are not yet known. For tech companies, the FED's expected interest rate hike, likely to be announced on January 26, brings uncertainty and makes investors rethink their investment strategy. Out of tech stocks, into value stocks. We look at one Company from each sector today.

Read

Commented by Mario Hose on January 20th, 2022 | 11:08 CET

Cardiol, Novavax, Valneva - Why it's worth buying now!

  • Investments

The trading week is coming to an end and on Thursday the German benchmark index DAX continues to trade below the psychological mark of 16,000 points at a level of 15,785 points and an increase of 0.10%. The rest of today and Friday remain to make a jump. It will probably depend on the guidance from the U.S., but at the hour, U.S. futures are all green. MDAX last traded at 34,135 points (+0.07%), TecDAX at 3,544 points (+0.07%) and SDAX at 15,626 points up 0.33%. Companies from the biotech sector are again in the focus of the investors today.

Read

Commented by Armin Schulz on January 19th, 2022 | 13:14 CET

Novavax, Meta Materials, BASF - Innovations offer great return opportunities

  • Technology

Companies that provide innovations to solve existing problems are ideal investment targets. Filtering out suitable candidates is the most critical task for an investor. Some products require little explanation. For companies developing advanced technologies, patents can give an indication of the Company's future prospects. In any case, the market that the products can serve should be analyzed. Today, we look at three innovative companies.

Read

Commented by Carsten Mainitz on January 18th, 2022 | 13:07 CET

Ayurcann, Novavax, Covestro - The stragglers are coming!

  • Cannabis

Humanity continues to find itself in the clutches of the Corona pandemic, the infection figures are rising, and the demand from politicians for mandatory vaccination is becoming louder and louder. While BioNTech and Pfizer vaccines and Moderna have dominated to date, new vaccine manufacturers are entering the market in the next wave. The situation is similar in the cannabis industry. After a boom about 3 years ago, the market leaders have since lost up to 80% of their value. Legalization and the rise of Cannabis 3.0. will pave the way for new companies.

Read

Commented by Mario Hose on January 14th, 2022 | 12:17 CET

Natural active ingredient against Covid-19: BioNTech, Cardiol, Novavax, Valneva in focus

  • Covid-19

At the end of the week, trading on the German stock exchanges has been rather slow so far. The German leading index DAX is quoted at a level of 15,922 points and thus around 0.01% up. The index of the second tier, MDAX, traded last at 34,626 points (-0.11%), TecDAX at 3,537 points (-0.67%) and SDAX at 15,904 points with 0.43% in the red. A study from the U.S. will influence the future development of vaccine manufacturers in connection with Covid-19, according to initial research.

Read